73 related articles for article (PubMed ID: 18723339)
1. Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone.
Zwolak P; Jasinski P; Terai K; Gallus NJ; Ericson ME; Clohisy DR; Dudek AZ
Eur J Cancer; 2008 Nov; 44(16):2506-17. PubMed ID: 18723339
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis.
Dudek AZ; Zwolak P; Jasinski P; Terai K; Gallus NJ; Ericson ME; Farassati F
Invest New Drugs; 2008 Feb; 26(1):13-24. PubMed ID: 17805485
[TBL] [Abstract][Full Text] [Related]
3. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model.
Murray LJ; Abrams TJ; Long KR; Ngai TJ; Olson LM; Hong W; Keast PK; Brassard JA; O'Farrell AM; Cherrington JM; Pryer NK
Clin Exp Metastasis; 2003; 20(8):757-66. PubMed ID: 14713109
[TBL] [Abstract][Full Text] [Related]
4. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.
Schueneman AJ; Himmelfarb E; Geng L; Tan J; Donnelly E; Mendel D; McMahon G; Hallahan DE
Cancer Res; 2003 Jul; 63(14):4009-16. PubMed ID: 12873999
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer.
Abrams TJ; Murray LJ; Pesenti E; Holway VW; Colombo T; Lee LB; Cherrington JM; Pryer NK
Mol Cancer Ther; 2003 Oct; 2(10):1011-21. PubMed ID: 14578466
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone.
Schroeder M; Viezens L; Wellbrock J; Fiedler W; Rüther W; Algenstaedt P; Hansen-Algenstaedt N; Schaefer C
J Surg Oncol; 2016 Apr; 113(5):515-21. PubMed ID: 26818116
[TBL] [Abstract][Full Text] [Related]
7. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation.
Cuneo KC; Geng L; Fu A; Orton D; Hallahan DE; Chakravarthy AB
Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):873-9. PubMed ID: 18514780
[TBL] [Abstract][Full Text] [Related]
8. Novel cytosine deaminase fusion gene enhances the effect of radiation on breast cancer in bone by reducing tumor burden, osteolysis, and skeletal fracture.
Goblirsch M; Zwolak P; Ramnaraine ML; Pan W; Lynch C; Alaei P; Clohisy DR
Clin Cancer Res; 2006 May; 12(10):3168-76. PubMed ID: 16707617
[TBL] [Abstract][Full Text] [Related]
9. Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases.
Zwolak P; Dudek AZ; Bodempudi VD; Nguyen J; Hebbel RP; Gallus NJ; Ericson ME; Goblirsch MJ; Clohisy DR
Int J Cancer; 2008 Feb; 122(3):681-8. PubMed ID: 17943718
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo.
Klenke FM; Abdollahi A; Bertl E; Gebhard MM; Ewerbeck V; Huber PE; Sckell A
BMC Cancer; 2007 Mar; 7():49. PubMed ID: 17367541
[TBL] [Abstract][Full Text] [Related]
11. [Effect of angiogenesis inhibitor SU6668 on the growth and metastasis of gastric cancer in SCID mice].
Jiang XT; Tao HQ; Zou SC
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jul; 9(4):335-7. PubMed ID: 16886118
[TBL] [Abstract][Full Text] [Related]
12. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
13. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer.
Hiraga T; Ueda A; Tamura D; Hata K; Ikeda F; Williams PJ; Yoneda T
Int J Cancer; 2003 Oct; 106(6):973-9. PubMed ID: 12918079
[TBL] [Abstract][Full Text] [Related]
14. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels.
Osusky KL; Hallahan DE; Fu A; Ye F; Shyr Y; Geng L
Angiogenesis; 2004; 7(3):225-33. PubMed ID: 15609077
[TBL] [Abstract][Full Text] [Related]
15. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
16. Assessment of anti-metastatic drug efficacy via localization and quantification of ex vivo murine bone tumor load using high-throughput MRI T1 parametric analysis.
Pagel MD; Baldwin SJ; Rader RK; Kotyk JJ
NMR Biomed; 2006 Feb; 19(1):1-9. PubMed ID: 16411252
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
18. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.
Marzola P; Degrassi A; Calderan L; Farace P; Nicolato E; Crescimanno C; Sandri M; Giusti A; Pesenti E; Terron A; Sbarbati A; Osculati F
Clin Cancer Res; 2005 Aug; 11(16):5827-32. PubMed ID: 16115922
[TBL] [Abstract][Full Text] [Related]
19. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
[TBL] [Abstract][Full Text] [Related]
20. A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo.
Takahashi H; Obata R; Tamaki Y
J Ocul Pharmacol Ther; 2006 Aug; 22(4):213-8. PubMed ID: 16910860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
